<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chen, Yimeng</style></author><author><style face="normal" font="default" size="100%">Wang, Xue</style></author><author><style face="normal" font="default" size="100%">Du, Feng</style></author><author><style face="normal" font="default" size="100%">Yue, Jian</style></author><author><style face="normal" font="default" size="100%">Si, Yiran</style></author><author><style face="normal" font="default" size="100%">Zhao, Xiaochen</style></author><author><style face="normal" font="default" size="100%">Cui, Lina</style></author><author><style face="normal" font="default" size="100%">Zhang, Bei</style></author><author><style face="normal" font="default" size="100%">Bei, Ting</style></author><author><style face="normal" font="default" size="100%">Xu, Binghe</style></author><author><style face="normal" font="default" size="100%">Yuan, Peng</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Association between homologous recombination deficiency and outcomes with platinum and platinum-free chemotherapy in patients with triple-negative breast cancer</style></title><secondary-title><style face="normal" font="default" size="100%">Cancer Biology &amp;amp; Medicine</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2023-02-15 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">155-168</style></pages><doi><style  face="normal" font="default" size="100%">10.20892/j.issn.2095-3941.2022.0525</style></doi><volume><style face="normal" font="default" size="100%">20</style></volume><issue><style face="normal" font="default" size="100%">2</style></issue><abstract><style  face="normal" font="default" size="100%">Objective: The choice of chemotherapeutic regimen for triple-negative breast cancer (TNBC) remains controversial. Homologous recombination deficiency (HRD) has attracted increasing attention in informing chemotherapy treatment. This study was aimed at investigating the feasibility of HRD as a clinically actionable biomarker for platinum-containing and platinum-free therapy.Methods: Chinese patients with TNBC who received chemotherapy between May 1, 2008 and March 31, 2020 were retrospectively analyzed with a customized 3D-HRD panel. HRD positivity was defined by an HRD score ≥ 30 or deleterious BRCA1/2 mutation. A total of 386 chemotherapy-treated patients with TNBC were screened from a surgical cohort (NCT01150513) and a metastatic cohort, and 189 patients with available clinical and tumor sequencing data were included.Results: In the entire cohort, 49.2% (93/189) of patients were identified as HRD positive (40 with deleterious BRCA1/2 mutations and 53 with BRCA1/2 intact with an HRD score of ≥ 30). In the first-line metastatic setting, platinum therapy was associated with longer median progression-free survival (mPFS) than platinum-free therapy [9.1 vs. 3.0 months; hazard ratio (HR), 0.43; 95% confidence interval 0.22–0.84; P = 0.01]. Among HRD-positive patients, the mPFS was significantly longer in those treated with platinum rather than platinum-free therapy (13.6 vs. 2.0 months; HR, 0.11; P = 0.001). Among patients administered a platinum-free regimen, HRD-negative patients showed a PFS significantly superior to that of HRD-positive patients (P = 0.02; treatment-biomarker P-interaction = 0.001). Similar results were observed in the BRCA1/2-intact subset. In the adjuvant setting, HRD-positive patients tended to benefit more from platinum chemotherapy than from platinum-free chemotherapy (P = 0.05, P-interaction = 0.02).Conclusions: HRD characterization may guide decision-making regarding the use of platinum treatment in patients with TNBC in both adjuvant and metastatic settings.</style></abstract></record></records></xml>